Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Volcano gets FDA approval for imaging systems
These two new product offerings now enable rotational IVUS and FFR to operate on the same integrated Volcano s5 Imaging System as Volcano’s previous line of phased array
These two new product offerings now enable rotational IVUS and FFR to operate on the same integrated Volcano s5 Imaging System as Volcano’s previous line of phased array
Preliminary data shows an increase of potency of the company’s first product candidate, DXL625 (CD20), for the prospective treatment of non-Hodgkin’s lymphoma. The study compared DXL625 with a
SkyePharma will also receive a small upfront payment. If the feasibility study is successful, full development activities will begin later in 2008. Frank Condella, CEO of SkyePharma, said:
The transaction will close on or before February 28, 2008, subject to satisfaction of customary closing conditions. Following the transaction, Green Hospital Supply’s ownership in Cytori will increase
Study 302 is a randomized, placebo-controlled, parallel-group, withdrawal-design Phase III study with an initial open-label dose titration and seven day open-label treatment period, followed by a 14-day double-blind
Merck employed four schemes to grab or maintain market share for drugs including Vioxx, Zocor, Cozaar, Fosamax, Maxalt, and Singulair, according to qui tam whistleblower lawyers Steven Cohen,
The data showed that Ardea’s lead NNRTI candidate, RDEA806, is a potent inhibitor of HIV, including the most common efavirenz resistant viruses. Oral dosing with RDEA806 achieved trough
Importantly, QuoNova’s QSB technology is an anti-virulence approach, which shows potential to prevent the consequences of infection from such drug-resistant bacteria, without inducing resistance itself. QuoNova recently demonstrated
The Phase I/II dose ranging study will evaluate the safety, tolerance, pharmacokinetics and activity of Triolex when administered orally for 28 days to patients with active, mild-to-moderate ulcerative
The BROADEN (BROdmann Area 25 DEep brain Neuromodulation) study will evaluate the safety and effectiveness of deep brain stimulation in patients with depression for whom currently-available treatments are